Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Citizens (CIA) Short-term Investments (2016 - 2025)

Citizens has reported Short-term Investments over the past 14 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Short-term Investments at $1.4 million for Q4 2025, down 75.11% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (down 75.11% YoY), and the annual figure for FY2025 was $1.4 million, down 75.11%.
  • Short-term Investments for Q4 2025 was $1.4 million at Citizens, down from $1.4 million in the prior quarter.
  • Over the last five years, Short-term Investments for CIA hit a ceiling of $22.7 million in Q2 2021 and a floor of $249000.0 in Q2 2023.
  • Median Short-term Investments over the past 5 years was $8.1 million (2023), compared with a mean of $9.8 million.
  • Peak annual rise in Short-term Investments hit 3141.45% in 2021, while the deepest fall reached 98.25% in 2021.
  • Citizens' Short-term Investments stood at $14.8 million in 2021, then decreased by 21.92% to $11.6 million in 2022, then plummeted by 54.43% to $5.3 million in 2023, then grew by 3.12% to $5.4 million in 2024, then plummeted by 75.11% to $1.4 million in 2025.
  • The last three reported values for Short-term Investments were $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $5.5 million (Q2 2025) per Business Quant data.